AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

AIM ImmunoTech reports promising clinical progress and financial stability

AIM ImmunoTech demonstrated strong clinical progress and financial stability, positioning the company well for future growth and potential partnerships.
While facing regulatory and operational challenges, the company's focus on expanding Ampligen's therapeutic applications and medical expertise presents significant opportunities for advancement.
Investors should monitor AIM ImmunoTech's continued progress in clinical trials and regulatory interactions, as positive outcomes could drive value creation and market expansion.

AIM ImmunoTech reports positive clinical progress and solid financial standing

AIM ImmunoTech's Q2 2024 Earnings Call highlighted significant progress in clinical trials for Ampligen, particularly in oncology indications.
Financially, the company maintains a solid cash position and continues to manage expenses to support ongoing operations and future milestones.
While facing challenges in trial design and cost management, AIM ImmunoTech remains well-positioned to capitalize on opportunities for growth and partnership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OCALA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine (“UPMC") has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1 – 5, 2023 in San Diego, CA and virtually.

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

OCALA, Fla., Oct. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC (“Azenova”), a professional business development (BD) consulting firm, to support efforts to partner AIM's pipeline programs with a particular focus on the company's lead asset, Ampligen®, for the treatment of various malignant solid tumors.

AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs

OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023. In addition to the presentation, the Company is proud to announce its sponsorship of the event.

AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC)

AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Bre

OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at the H.C. Wainwright 25 th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.

AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, after careful deliberation, its Board of Directors (the “Board”) unanimously concluded that the notice (the “Notice”) submitted by Ted D. Kellner purporting to nominate himself, Robert L. Chioini and Todd Deutsch for election to the Company's Board at the 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) fails to comply with the Company's Bylaws (the “Bylaws”) and.

AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements

AIM ImmunoTech Inc. (NYSE:AIM ) Q2 2023 Earnings Conference Call August 15, 2023 8:30 AM ET Company Participants Thomas Equels - Executive Vice Chairman, Chief Executive Officer and President Christopher McAleer - Scientific Officer Conference Call Participants James Molloy - Alliance Global Partners Edward Woo - Ascendiant Capital Operator Hello and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in listen-only mode.

AIM ImmunoTech Inc. (AIM) Q2 2023 Earnings Call Transcript

– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023

AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update

Aimia Inc. (OTCPK:AIMFF) Q2 2023 Earnings Conference Call August 11, 2023 8:30 AM ET Company Participants Albert Matousek - Head of Investor Relations and Communications Phil Mittleman - Chief Executive Officer Michael Lehman - President Steven Leonard - Chief Financial Officer Conference Call Participants Surinder Thind - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the Aimia Inc. Second Quarter 2023 Results Conference Call. [Operator Instructions] I would now like to turn the conference over to Mr.

Aimia Inc. (AIMFF) Q2 2023 Earnings Call Transcript

OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company's Q2 2023 operational and financial results on Tuesday, August 15, 2023 at 8:30 AM ET.

AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast

OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company's Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions (“AMP-518”).

AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

OCALA, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a notice that the Company has learned that unknown person(s) and/or organization(s) are claiming to represent AIM ImmunoTech Europe and are using the Company's name without authorization. Specifically, there is a LinkedIn profile promoting misinformation related to AIM's ongoing clinical activities, and the profile purports to be linked to the organization Clavinvest. The unauthorized and unaffiliated profile uses AIM's logo and copyrighted imagery to provide the impression that it has a formal relationship with AIM concerning AIM's activities with Erasmus Medical Center in the Netherlands and Prof. C.H.J. van Eijck. Among other things, the LinkedIn profile promotes inaccurate information on its relationship with AIM related to the ongoing clinical efforts in pancreatic cancer, refers the reader to an entity that could falsely be interpreted to be AIM's European subsidiary and implies that this entity will be raising funds.

AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has enrolled and dosed the first subject in the company's Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions (“AMP-518”).

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K.

AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series

Findings support efforts in ongoing Early Access Program and upcoming clinical trials, and suggest Ampligen's potential to reduce tumor cell growth and boost immune response in pancreatic cancer patients with sufficient tumor levels of TLR-3 Findings support efforts in ongoing Early Access Program and upcoming clinical trials, and suggest Ampligen's potential to reduce tumor cell growth and boost immune response in pancreatic cancer patients with sufficient tumor levels of TLR-3

AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research

Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Can

OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K Equels, M.S.

AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Company's priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the treatment of pancreatic cancer (AMP-270) Ongoing progress toward Phase 1 data in clinical development program of Ampligen for the treatment of early-stage triple negative breast cancer Significant findings from a new analysis support the potential to identify patients with LAPC that could respond better to Ampligen Company bolsters patent portfolio for Ampligen as a potential therapy against Ebola virus disease OCALA, Fla., June 12, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today provided an update on its ongoing clinical development programs evaluating Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immune-modulator with broad spectrum activity.

AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

AIM ImmunoTech Inc. (NYSE:AIM ) Q1 2023 Earnings Conference Call May 16, 2023 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Ph.D. Scientific Officer Conference Call Participants James Molloy - Alliance Global Partners Ed Woo - Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast.

AIM ImmunoTech Inc. (AIM) Q1 2023 Earnings Call Transcript

– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023 – Lead clinical program, Phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter

AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update

OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — announced today that management will host a conference call and webcast to discuss the Company's Q1 2023 operational and financial results on Tuesday, May 16, 2023 at 8:30 AM ET.

AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast

Company's SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry

AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D.

Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditions Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditions

AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2022 Earnings Conference Call April 3, 2023 8:30 AM ET Company Participants Thomas Equels - CEO Chris McAleer - Ph.D. Scientific Officer Conference Call Participants Jason McCarthy - Maxim Ed Woo - Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech Inaugural Fiscal Year 2022 Update Conference Call and Webcast.

AIM ImmunoTech Inc. (AIM) Q4 2022 Earnings Call Transcript

– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs

News for AIM ImmunoTech Inc Stock (AIM)